← boardnext 2026-12
ALDX
Aldeyra Therapeutics, Inc.distress 0/10 · well-funded / low risk$1.69-1%today-71% from 52w high
Infectious Disease 1Ophthalmology 1
Lead: dry eye disease
Revenue
pre-revenue
Liquidity
$81M
Runway
3.1 yrs
Shares 1y
+1%
Price & events
-67.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.6%
1D
-1.7%
1W
-16.3%
1M
+5.6%
3M
-67.4%
6M
-69.4%
1Y
-57.9%
2Y
-81.4%
5Y
-74.1%
All
Overview
- Market Cap
- $101.94M
- Enterprise Value
- $36.94M
- Volume
- 92.01K
- 52 Week Range
- $1.24 – $5.89
- Total Shares
- 60.32M
- Float Shares
- 52.68M
- Short %
- 9.72%
- % Held by Insiders
- 3.60%
- % Held by Institutions
- 62.79%
- RVOL
- 0.05x
- Beta
- 1.15
Pipeline stages · 3 programs
ICM ADX-2191 injection, Monthly ADX-2191 injection
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ADX-629
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-02-14 | Phase 3 | ICM ADX-2191 injection, Monthly ADX-2191 injection | Primary Vitreoretinal Lymphoma | — | recruiting |
| 2025-06-18 | Phase 2 | ADX-629orphanfast track | Alcohol Hepatitis | 4 | completed |
| 2025-02-27 | Phase 3 | Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution | Dry Eye Disease | 116 | completed |
Catalyst news & presentations · 14
- 2026Guided 40%regulatory submissionFiled (NDA/BLA)ADX-248 · Anticipated IND filing for ADX-248SEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-03-17crlreproxalap · FDA issued CRL for reproxalap NDA citing lack of substantial evidence and inconsistent study results for dry eye disease.SEC 8-K
- second half of 2025trial initiationsecondaryADX-2191 · Trial comparing single vs eight intraocular injections of ADX-2191 in up to 20 patientsSEC 8-K
- December 16, 2025PDUFAPDUFAreproxalap · PDUFA target action date for reproxalap NDASEC 8-K
- 2025-12-15pdufa extensionreproxalap · FDA extended the PDUFA date for the NDA for dry eye disease.SEC 8-K
- 2025-10-28trial discontinuedADX-629 · Clinical development of ADX-629 discontinued pending investigator-sponsored testing in Sjögren-Larsson SyndromeSEC 8-K
- within 30 days of submissionfiling acceptanceFiled (NDA/BLA)reproxalap · FDA acceptance of NDA resubmission for reviewSEC 8-K
- second quarter of 2025readoutreproxalap · Results from two additional dry eye disease trialsSEC 8-K
- mid-year 2025regulatory submissionFiled (NDA/BLA)reproxalap · NDA resubmission plannedSEC 8-K
- 2025-06-26spaADX-2191 · FDA agrees to Special Protocol Assessment for ADX-2191 trial design in PVRLSEC 8-K
- 2025-04-03crlreproxalap · FDA issued Complete Response Letter for reproxalap NDA citing lack of efficacy in ocular symptoms.SEC 8-K
- April 2, 2025PDUFAPDUFAreproxalap · PDUFA date for reproxalap NDA resubmissionSEC 8-K
- 2024-11-15partnershipreproxalap · Expanded exclusive option agreement with AbbVie, including pre-commercial activities and amended option exercise periodSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $7 (+324% upside) · 6 analysts
- 2026-03-18HC Wainwright & Co.Buy → Neutral
- 2025-11-10BTIGBuy
- 2025-05-19HC Wainwright & Co.Buy
- 2025-04-07BTIGBuy
- 2025-04-04HC Wainwright & Co.Buy
- 2025-03-03HC Wainwright & Co.Buy
Competitors — dry eye disease
Recent news
- 2026-07-22Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Reach Out - ACCESS Newswire
- 2026-07-20Price to sales forward of Aldeyra Therapeutics, Inc. – FWB:137 - TradingView
- 2026-07-20Revenue per share of Aldeyra Therapeutics, Inc. – FWB:137 - TradingView
- 2026-07-20Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Reach Out - ACCESS Newswire
- 2026-07-18Aldeyra Therapeutics Inc. (ALDX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
- 2026-07-15Aldeyra Therapeutics (NASDAQ: ALDX) advances FDA dialogue on reproxalap NDA - Stock Titan
- 2026-07-10Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
- 2026-07-10Aldeyra Therapeutics: What Comes Next After Reproxalap's Third CRL (NASDAQ:ALDX) - Seeking Alpha
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.